Phibro Animal Health Corporation: stock overview

PAHCNASDAQHealthcare · Pharmaceutical Preparations

Price

$35.97

November 13, 2026Market cap $1.5B

DCF calculator

What Ploutos Investor adds for Phibro Animal Health

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 15 fiscal years, from FY2012
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Phibro Animal Health had revenue of $1.5B over the last 12 months and net income of $103M, a net margin of 6.7%. Revenue grew by 12.7% a year on average over the last 5 years. At $35.97 the shares trade at a P/E of 14.2, against a median of 16.4 over the last 4 fiscal years. It has net debt of $528M. It pays a dividend yielding 1.33%.

From its SEC filings (latest fiscal year to June 30, 2026) and the price of November 13, 2026.

Its SEC filings
Market cap
$1.5B
40.55M shares
P/E
14.2
Today14.2
Median16.4
Revenue, 12 months
$1.5B
+12.7% a year over 5 years
Net margin
6.7%
FY2025: 3.7%, above 64% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2024–FY2026 fiscal years

+22.1% a year over 2 years

  • FY2026Jun 30, 202610-K
    Revenue$1.5B
  • FY2025Jun 30, 202510-K
    Revenue$1.3B
  • FY2024Jun 30, 202410-K
    Revenue$1.0B

Fiscal years in figures

PAHC's revenue, profit, cash flow and dividend with each year-end price, from FY2012 to FY2023, 12 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $1.0B
$1.5B
Enterprise value 
$2.0B
P/E 
14.2
EV / EBIT 
10.3
EV / Revenue 
1.3
P/B 3-year median: 3.3
3.5
FCF yield 3-year median: 4.0%
1.5%
Earnings yield 3-year median: 4.7%
7.0%

Profitability

Gross margin 
33.8%
Operating margin 
12.5%
Net margin 3-year median: 3.7%
6.7%
ROIC 
14.4%
ROIC, 5-year average 
18.9%
ROE 
28.4%

Growth

Revenue, yearly change 
+17.1%
EPS, yearly change 
+104.2%
FCF, yearly change 
-76.4%
Revenue, average a year 
+12.7%
EPS, average a year 
+12.6%

The yearly change compares FY2026 with FY2025.

Balance sheet

Cash 
$83M
Total debt 
$665M
Of which operating leases 
$54M
Net debt 
$528M
Net debt / EBITDA 
2.2x
Interest cover 
4.2x
Current ratio 
3.20

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 3-year median: 1.9%
1.33%
Buybacks 
–
Total returned 
1.33%
Shares, yearly change 
+0.1%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

30.9%

Above 33% of the 141 companies in its industry, and 40% of all.

Operating margin

8.5%

Above 68% of the 285 companies in its industry, and 61% of all.

Net margin

3.7%

Above 64% of the 302 companies in its industry, and 48% of all.

ROE

14.5%

Above 75% of the 267 companies in its industry, and 75% of all.

ROA

3.4%

Above 66% of the 313 companies in its industry, and 64% of all.

Revenue growth

27.4%

Above 79% of the 292 companies in its industry, and 88% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
PHIBRO ANIMAL HEALTH CORP
CIK
1069899
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
June 30
Latest annual report
June 30, 2026
Reporting currency
USD
Shares
40.55M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Phibro Animal Health's filings show?

These are Phibro Animal Health's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about PAHC

Didn't find what you were looking for?

Ask us
What is PAHC's market cap?

Phibro Animal Health Corporation's market cap is $1.5B, at a price of $35.97 on November 13, 2026 and 40.55M shares.

What is PAHC's P/E?

PAHC's P/E is 14.2, on earnings per share of $2.51 over the last 12 months. The median over the last 4 fiscal years was 16.4.

How much revenue does PAHC have?

Phibro Animal Health had revenue of $1.5B over the last 12 months. Over the last 5 years it changed by +12.7% a year on average.

Does PAHC pay a dividend?

Yes. Phibro Animal Health paid $0.48 per share over the last 12 months, a yield of 1.33% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Phibro Animal Health Corporation's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.